Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

• Published in: International journal of molecular sciences 2023-10, Vol.24 (19), p.14562
• Main Authors: Jamshidi, Parnian, Farsi, Yeganeh, Nariman, Zahra, Hatamnejad, Mohammad Reza, Mohammadzadeh, Benyamin, Akbarialiabad, Hossein, Nasiri, Mohammad Javad, Sechi, Leonardo A
• Format: Article
• Language: English
• Subjects: Analysis; Bias; Clinical trials; Colonoscopy; fecal microbiota transplantation; Feces; gastrointestinal microbiome; Infectious diseases; Irritable bowel syndrome; Medical research; Medicine, Experimental; Meta-analysis; Microbiota; Microbiota (Symbiotic organisms); Patient satisfaction; Patients; randomized controlled trial; Review; Systematic review; Transplants & implants
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms241914562

Irritable bowel syndrome (IBS) poses a significant challenge due to its poorly understood pathogenesis, substantial morbidity, and often inadequate treatment outcomes. The role of fecal microbiota transplantation (FMT) in managing IBS symptoms remains inconclusive. This systematic review and meta-analysis aimed to ascertain the effectiveness of FMT in relieving symptoms in IBS patients. A thorough search was executed on PubMed/Medline and Embase databases until 14 June 2023, including all studies on FMT use in IBS patients. We examined the efficiency of FMT in reducing patients’ symptoms overall and in particular subgroups, classified by placebo preparation, FMT preparation, frequency, and route of administration. Among 1015 identified studies, seven met the inclusion criteria for the meta-analysis. The overall symptomatology of FMT-treated IBS patients did not significantly differ from the control group (Odds Ratio (OR) = 0.99, 95% Confidence Interval (CI) 0.39–2.5). Multiple doses of FMT compared with non-FMT placebo, or single-donor FMT therapy compared with autologous FMT placebo also showed no significant benefit (OR = 0.32, 95%CI (0.07–1.32), p = 0.11, and OR = 1.67, 95%CI (0.59–4.67), p = 0.32, respectively). However, a single dose of multiple-donor FMT administered via colonoscopy (lower gastrointestinal (GI) administration) significantly improved patient symptoms compared with autologous FMT placebo (OR = 2.54, 95%CI (1.20–5.37), p = 0.01, and OR = 2.2, 95%CI (1.20–4.03), p = 0.01, respectively). The studies included in the analysis showed a low risk of bias and no publication bias. In conclusion, lower GI administration of a single dose of multiple-donor FMT significantly alleviates patient complaints compared with the autologous FMT used as a placebo. The underlying mechanisms need to be better understood, and further experimental studies are desired to fill the current gaps.